Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,892.00-0.12%ETH$2,284.26+0.69%GOLD$3,908.50+0.25%OIL$99.37-4.56%
Smart Investors Daily
SID Premium
Actinium Pharmaceuticals, Inc. logo

AMEX · ATNM

Actinium Pharmaceuticals, Inc.

Healthcare · Biotechnology

$1.48

Down-$0.05 (-3.27%)

Updated Nov 2, 2026, 10:07 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
45.55M
P/E ratio
-1.32
Dividend yield
0.00%
52-week range
$0.74 – $1.72
Volume
157.72K
Avg. volume
205.89K

Price performance · ATNM

ATNM price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ATNM closed at $1.48 after 20 trading sessions, up 23.33% for the selected period.

Last close
$1.48
Period change
+23.33%
Period low
$0.97
Period high
$1.60
Daily close
View OHLC price history
ATNM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$1.51$1.535$1.45$1.48157.72K
Oct 29, 2026$1.38$1.56$1.38$1.53181.67K
Oct 28, 2026$1.40$1.42$1.35$1.3856.56K
Oct 27, 2026$1.40$1.55$1.40$1.42106.95K
Oct 26, 2026$1.50$1.53$1.36$1.40205.86K
Oct 23, 2026$1.60$1.63$1.469$1.52242.01K
Oct 22, 2026$1.33$1.66$1.33$1.60828.82K
Oct 21, 2026$1.38$1.4087$1.33$1.38358.23K
Oct 20, 2026$1.36$1.50$1.3501$1.40901.05K
Oct 19, 2026$1.14$1.40$1.13$1.32658.4K
Oct 16, 2026$1.09$1.15$1.05$1.13174.39K
Oct 15, 2026$0.95$1.07$0.95$1.06143.24K
Oct 14, 2026$0.99$1.0225$0.9518$0.974684.64K
Oct 13, 2026$1.07$1.07$0.9955$0.999589.25K
Oct 12, 2026$1.09$1.09$1.0292$1.0698.46K
Oct 9, 2026$1.09$1.12$1.07$1.10105.76K
Oct 8, 2026$1.09$1.10$1.06$1.08104.87K
Oct 7, 2026$1.08$1.12$1.05$1.07100.09K
Oct 6, 2026$1.20$1.22$1.02$1.11439.58K
Oct 5, 2026$1.16$1.24$1.16$1.20115.03K

Latest ATNM news

The latest Smart Investors Daily articles mentioning ATNM.

Stock researchCompany · Overview

ATNM research

Overview

Company profile and research snapshot.

Company profile

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$11.07
Implied upside
—
Analysts
11
ATNM recent ratings
DateFirmRatingTarget
Mar 31, 2026Stephens & Co.Overweight—
Jun 24, 2025HC Wainwright & Co.Buy—
May 12, 2025HC Wainwright & Co.Buy—
Apr 28, 2025HC Wainwright & Co.Buy—
Apr 1, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced that the first‑in‑human Phase 1 study of ATNM‑400, a HER3-targeted, non-PSMA radiotherapy, in metastatic castration‑resistant prostate cancer (mCRPC) will be featured at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23⁠–⁠27, 2026, in Madrid, Spain.

Yahoo · Oct 20, 2026

Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced encouraging initial clinical results from the first‑in‑human Phase 1 study of ATNM‑400 in metastatic castration‑resistant prostate cancer (mCRPC). The findings, presented in an oral presentation on October 19 at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By